Interferon-β therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and Interleukin-10 production

Annals of Neurology

Volumn 51, Issue 2, 2002, Pages 165-174

  Byrnes, Adriana A ^a   McArthur, Justin C ^a   Karp, Christopher L ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12;

ADULT; AGED; ALLERGIC ENCEPHALOMYELITIS; ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; REMISSION;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; FEMALE; HUMANS; INTERFERON-BETA; INTERLEUKIN-10; INTERLEUKIN-12; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 0036154417     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10084     Document Type: Article

References (62)

1. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
2. Natural history of multiple sclerosis
3. Interferon-beta in multiple sclerosis: Altering the balance of interleukin-12 and interleukin-10?
4. Interferon beta in multiple sclerosis: Is IL-12 suppression the key?
5. Interleukin-12: A cytokine at the interface of inflammation and immunity
6. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10
7. IL-12 induces human T cells secreting IL-10 with IFN-gamma
8. Interleukin-12: Amiss in MS
9. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease
10. The pattern of production of cytokine mRNAs is markedly altered at the onset of multiple sclerosis
11. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis
12. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis
13. Interferon-alpha/beta inhibition of interleukin 12 and interferon-gamma production in vitro and endogenously during viral infection
14. Type I IFNs inhibit human dendritic cell IL-12 production and Thl cell development
15. Type I interferons and IL-12: Convergence and cross-regulation among mediators of cellular immunity
16. IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: Relevance to IFN-beta-1b therapeutic effects in multiple sclerosis
17. Interferon beta induces interleukin-10 expression: Relevance to multiple sclerosis
18. Immunomodulatory effects of interferon beta-la in multiple sclerosis
19. Interferon (IFN)beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients
20. In vivo effects of interferon beta-la on immunosuppressive cytokines in multiple sclerosis
21. Contrasting responses to interferon beta-1b treatment in relapsing-remitting multiple sclerosis: Does baseline interleukin-12p35 messenger RNA predict the efficacy of treatment?
22. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
23. Impaired interleukin 12 production in human immunodeficiency virus-infected patients
24. Molecular analysis of decreased interleukin-12 production in persons infected with human immunodeficiency virus
25. Natural measles causes prolonged suppression of interleukin-12 production
26. Potent suppression of IL-12 production from monocytes and dendritic cells during endotoxin tolerance
27. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy
28. A gender gap in autoimmunity
29. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity
30. Expression of IL-12 in CNS and lymphoid organs of mice with experimental allergic encephalitis
31. Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis
32. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: Dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor alpha and tumor necrosis factor beta
33. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12
34. IL-12 unmasks latent autoimmune disease in resistant mice
35. Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat
36. Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus)
37. IL-10 fails to abrogate experimental autoimmune encephalomyelitis
38. Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system
39. Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis
40. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery
41. Coupling of peripheral tolerance to endogenous interleukin-10 promotes effective modulation of myelin-activated T cells and ameliorates experimental allergic encephalomyelitis
42. Interleukin-10 prevents experimental allergic encephalomyelitis in rats
43. Acceleration of experimental autoimmune encephalomyelitis in inrerleukin-10-deficient mice: Roles of interleukin-10 in disease progression and recovery
44. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin-12 cytokine in multiple sclerosis lesions
45. Interleukin-12 and perforin mRNA expression is augmented in blood mononuclear cells in multiple sclerosis
46. The nature of heterophilic antibodies and their role in immunoassay interference
47. Increased release of interleukin-12p40 in MS: Association with intracerebral inflammation
48. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis
49. Increased interleukin-12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand
50. Taxol increases steady-state levels of lipopolysaccharide-inducible genes and protein-tyrosine phosphorylation in murine macrophages
51. The interleukin-12-mediated pathway of immune events is dysfunctional in human immunodeficiency virus-infected individuals
52. Measles virus infection induces terminal differentiation of human thymic epithelial cells
53. Increased in vitro induced CD4+ and CD8+ T cell IFN-gamma and CD4+ T cell IL-10 production in stable relapsing multiple sclerosis
54. Defective regulation of IFN-gamma and IL-12 by endogenous IL-10 in progressive MS
55. Augmented type 1 cytokines and human endogenous retroviruses specific immune responses in patients with acute multiple sclerosis
56. Modulation of the IL-10/IL-12 cytokine circuit by interferon-beta inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis
57. Selective loss of type 1 interferon-induced STAT4 activation caused by a minisatellite insertion in mouse Stat2
58. Certified professionals: CD4(+)CD25(+) suppressor T cells
59. Selective expression of an interleukin-12 receptor component by human T helper 1 cells
60. Effects of interferon-alpha on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells
61. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo
62. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement